Ultragenyx Pharmaceutical Inc. (FRA:UP0)

Market Cap	2.76B
Revenue (ttm)	537.46M
Net Income (ttm)	-494.19M
Shares Out	n/a
EPS (ttm)	-5.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350
Average Volume	28
Open	29.20
Previous Close	29.00
Day's Range	29.20 - 29.80
52-Week Range	22.40 - 46.60
Beta	n/a
RSI	58.03
Earnings Date	Feb 13, 2026

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 1,294
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UP0

Financial Performance

In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.

Financial numbers in USD